Elexacaftor, also known as VX-445 and WHO 11180, is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function in patients with cystic fibrosis when administered with tezacaftor and ivacaftor (VX-445–tezacaftor–ivacaftor).
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019018395. (2019).
Abela, Alexander Russell; Alcacio, Timothy; Anderson, Corey; Angell, Paul Timothy; Baek, Minson; Clemens, Jeremy J.; Cleveland, Thomas; Ferris, Lori Ann; Grootenhuis, Peter Diederik Jan; Gross, Raymond Stanley; Gulevich, Anton; Hadida Ruah, Sara Sabina; Hsia, Clara Kuang-Ju; Hughes, Robert M.; Joshi, Pramod Virupax; Kang, Ping; Keshavarz-Shokri, Ali; Khatuya, Haripada; Krenitsky, Paul John; Mccartney, Jason; Miller, Mark Thomas; Paraselli, Prasuna; Pierre, Fabrice Jean Denis; Shi, Yi; Shrestha, Muna; Siesel, David Andrew; Stavropoulos, Kathy; Termin, Andreas P.; Uy, Johnny; Van Goor, Fredrick F.; Young, Tomothy John; Zhou, Jinglan. Preparation of N-heteroaroylsulfonamide derivatives as cystic fibrosis transmembrane conductance regulator modulators for treatment of cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2018107100. (2018).
